Coronavirus News and Research

RSS

Research shows intestinal parasite infestations reduce COVID-19 severity

Now, new research out of Mekelle, Ethiopia, examines the role of parasitic infestation on the prognosis of COVID-19. The research paper, which appears on the preprint server medRxiv, shows that intestinal parasitosis is protective against severe COVID-19.

4 Feb 2021

Greater muscle strength associated with lower risk of COVID-19 hospitalization

A new preprint research paper posted to the medRxiv* server discusses the results of a study exploring the relationship between increased muscle strength and hospitalization for severe COVID-19.

4 Feb 2021

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Imaging SARS-CoV-2 with a helium ion microscope for the first time

Scientists at Bielefeld University's Faculty of Physics have succeeded for the first time in imaging the SARS-CoV-2 coronavirus with a helium ion microscope.

4 Feb 2021

Study: Only 14% of the Bernese population developed antibodies against SARS-CoV-2

In the canton of Bern, only 14% of the adult population were infected with the coronavirus and developed antibodies against SARS-CoV-2.

4 Feb 2021

Study shows psychological impact of perceived COVID-19 health threat among Black Americans

As the coronavirus pandemic continues to devastate communities worldwide, Black Americans who face racial discrimination in hospitals and doctor's offices weather additional stresses that can exacerbate threats from COVID-19.

4 Feb 2021

COVID-19 vaccination alone may not end the pandemic

A simulation-based study conducted at the Miami University, USA, has revealed that vaccination of the general population against coronavirus disease 2019 (COVID-19) alone is not sufficient to control the pandemic, given the current availability and implementation strategies.

4 Feb 2021

Emory MVA COVID-19 vaccine proven safe and effective in mice and monkeys

Researchers at Yerkes National Primate Research Center, Emory University, have developed a COVID-19 vaccine that has proven safe and effective in mice and monkeys.

4 Feb 2021

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.

4 Feb 2021

Experimental vaccine diminishes fatal respiratory effects of synthetic opioids

As the opioid epidemic raged on with an even greater force during COVID-19, the Scripps Research laboratory of chemist Kim Janda, PhD, has been working on new therapeutic interventions that may be able to prevent the bulk of deaths from opioid overdose.

4 Feb 2021

Researchers call for trials of rapamycin to treat COVID-19

Researchers in the United States, China, and the UK have called for immediate large-scale clinical trials of an antibiotic called rapamycin as a prophylactic and treatment approach to coronavirus disease 2019 (COVID-19) in older individuals.

4 Feb 2021

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Feb 2021

KHN’s ‘What the Health?’: Covid and kids

Nearly a year into the pandemic, many public schools are still closed to in-person instruction. But while there is increasing evidence that schools are not a major source of infection, teachers and staffers remain concerned about going back to class before they are vaccinated.

4 Feb 2021

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

After reanalyzing data from 500,000 people in Israel who received the Pfizer vaccine, researchers suggest a single dose provides sufficient immunity after about 21 days, thus providing support for the UK’s decision to delay the second dose to 12 weeks.

4 Feb 2021